Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study

BackgroundProgrammed death-1 (PD-1) inhibitors plus tyrosine kinase inhibitors (TKIs) combination therapy are considered as a first-line treatment recommendation for advanced hepatocellular carcinoma (HCC). However, patients with hyperbilirubinemia are excluded from this therapeutic option due to li...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Shida Pan, Jianing Wang, Jiahe Tian, Yilin Wang, Siyu Wang, Yingying Yu, Fengyi Li, Yan-Mei Jiao, Yingjuan Shen, Luo Yang, Xiaomeng Liu, Qin Qiu, Junqing Luan, Fu-Sheng Wang, Fanping Meng
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2025-03-01
Σειρά:	Frontiers in Immunology
Θέματα:	hepatocellular carcinoma hyperbilirubinemia programmed death 1 immunotherapy survival
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530477/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!